ProNAi Therapeutics (DNAI) Posts Wider Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
ProNAi Therapeutics Reports Second Quarter 2015 Results
August 21, 2015 7:00 AM EDTCompleted Upsized Initial Public Offering, Raising Gross Proceeds of $158.4 MillionAdvanced Clinical Programs for PNT2258 in DLBCL and Richter's Transformed CLLStrengthened Management Team and Board of Directors
VANCOUVER, Aug. 21, 2015 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today reported its financial and operational results for the second quarter of 2015.
"During the second quarter we continued to advance our clinical programs for PNT2258, opening clinical trial sites and enrolling patients into our Phase 2... More
